Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.
Lange T, Niederwieser C, Gil A, Krahl R, von Grünhagen U, Al-Ali HK, Jentsch-Ullrich K, Spohn C, Lakner V, Assmann M, Junghanss C, Cross M, Hehlmann R, Deininger M, Pfirrmann M, Niederwieser D. Lange T, et al. Among authors: krahl r. Leuk Lymphoma. 2020 Dec;61(12):2821-2830. doi: 10.1080/10428194.2020.1786556. Epub 2020 Jul 16. Leuk Lymphoma. 2020. PMID: 32672489 Clinical Trial.
Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
Mantovani L, Hasenclever D, Krahl R, Pönisch W, Herold M, Pasold R, Fiedler F, Dölken G, Kämpfe D, Schmoll HJ, Súbert R, Kubel M, Niederwieser D, Helbig W; East German Hematology and Oncology Group (OSHO). Mantovani L, et al. Among authors: krahl r. Leuk Lymphoma. 2002 Feb;43(2):265-74. doi: 10.1080/10428190290006035. Leuk Lymphoma. 2002. PMID: 11999557 Clinical Trial.
The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients.
Müller C, Hennig E, Franke C, Krahl R, Leiblein S, Niederwieser D, Deininger MW. Müller C, et al. Among authors: krahl r. Cancer Genet Cytogenet. 2002 Jul 15;136(2):149-50. doi: 10.1016/s0165-4608(01)00661-6. Cancer Genet Cytogenet. 2002. PMID: 12237241 No abstract available.
The effect of prior exposure to imatinib on transplant-related mortality.
Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boqué C, Faber E, Nagler A, Pogliani E, Russell N, Volin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D; European Blood and Marrow Transplantation Group. Deininger M, et al. Among authors: krahl r. Haematologica. 2006 Apr;91(4):452-9. Haematologica. 2006. PMID: 16585011
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
Messerer D, Engel J, Hasford J, Schaich M, Ehninger G, Sauerland C, Büchner T, Schumacher A, Krahl R, Niederwieser D, Krauter J, Ganser A, Creutzig U, Döhner H, Schlenk RF; German AML Intergroup. Messerer D, et al. Among authors: krahl r. Haematologica. 2008 Jun;93(6):826-33. doi: 10.3324/haematol.11987. Epub 2008 May 10. Haematologica. 2008. PMID: 18469349 Free article.
Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading?
Eisfeld AK, Westerman M, Krahl R, Leiblein S, Liebert UG, Hehme M, Teupser D, Niederwieser D, Al-Ali HK. Eisfeld AK, et al. Among authors: krahl r. Adv Hematol. 2011;2011:491058. doi: 10.1155/2011/491058. Epub 2011 May 5. Adv Hematol. 2011. PMID: 21687645 Free PMC article.
51 results